You are here » Home » Companies » Company Overview » Aurobindo Pharma Ltd

Aurobindo Pharma Ltd.

BSE: 524804	Sector: Health care
NSE: AUROPHARMA	ISIN Code: INE406A01037

BSE 00:00 | 27 May

529.60

-5.90
(-1.10%)

OPEN

535.50

HIGH

543.00

LOW

524.50

NSE 00:00 | 27 May

529.70

-6.15
(-1.15%)

OPEN

540.00

HIGH

543.20

LOW

525.00

Add to Watchlist | Add to Portfolio

OPEN	535.50
PREVIOUS CLOSE	535.50
VOLUME	121279
52-Week high	1038.30
52-Week low	514.50
P/E	20.35
Mkt Cap.(Rs cr)	31,029
Buy Price	0.00
Buy Qty	0.00
Sell Price	0.00
Sell Qty	0.00

OPEN	535.50
CLOSE	535.50
VOLUME	121279
52-Week high	1038.30
52-Week low	514.50
P/E	20.35
Mkt Cap.(Rs cr)	31,029
Buy Price	0.00
Buy Qty	0.00
Sell Price	0.00
Sell Qty	0.00

Aurobindo Pharma Ltd. (AUROPHARMA) - Latest News & Headlines

Aurobindo hits 2-year low; dips 11% in a week on USFDA's 6 observations

12.42 pm | 17 May 2022 | Business Standard

Analysts at ICICI Securities expect Aurobindo Pharma's adjusted PAT to de-grow 30.4 per cent year-on-year (YoY) to Rs 557.90 crore in the March 2022 q...
Aurobindo's Veritaz acquisition unlikely to add much value: Analysts

4.42 pm | 29 Mar 2022 | Business Standard

Deal is nonetheless a stepping stone in the drug firm's strategic plan to focus on domestic formulations market, where it aims to have Rs 1,000-cr sal...
Aurobindo Pharma acquires Veritaz' domestic business for Rs 171 cr

12.18 am | 29 Mar 2022 | Business Standard

Move marks Aurobindo's increasing focus on Indian market
Nifty Pharma may have bottomed out; Aurobindo, Glenmark can rally up to 10%

12.54 pm | 21 Mar 2022 | Business Standard

The Nifty Pharma index has crossed its near-term resistance at 13,700, and may spurt another 1.5 per cent.
Select pharma shares gain on tie-up for Pfizer Covid-19 oral treatment drug

12.29 pm | 21 Mar 2022 | Business Standard

Among individual stocks, Aurobindo Pharma was the top gainer, which rallied 8 per cent to Rs 688.90 on the BSE in intra-day trade.
Aurobindo Pharma net profit dips 22% to Rs 604 cr in December quarter

8.04 pm | 9 Feb 2022 | Press Trust of India

The Hyderabad-based drug maker had reported a consolidated net profit of Rs 777.3 crore in the same period of previous fiscal
Aurobindo Pharma down 5% on USFDA warning letter for Hyderabad unit

1.05 am | 15 Jan 2022 | Business Standard

The company believes that this will not impact the existing business from this facility.
Stocks to Watch: Hero MotoCorp, Aurobindo, Neogen, SPARC, telecom shares

7.41 am | 6 Dec 2021 | Business Standard

Telecom shares may be in demand on credit of bank guarantee to the telcos